2aid

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="2aid" size="450" color="white" frame="true" align="right" spinBox="true" caption="2aid, resolution 1.9&Aring;" /> '''STRUCTURE OF A NON-P...)
Line 1: Line 1:
-
[[Image:2aid.gif|left|200px]]<br />
+
[[Image:2aid.gif|left|200px]]<br /><applet load="2aid" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="2aid" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="2aid, resolution 1.9&Aring;" />
caption="2aid, resolution 1.9&Aring;" />
'''STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN'''<br />
'''STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN'''<br />
==Overview==
==Overview==
-
A stable, non-peptide inhibitor of the protease from type 1 human, immunodeficiency virus has been developed, and the stereochemistry of, binding defined through crystallographic three-dimensional structure, determination. The initial compound, haloperidol, was discovered through, computational screening of the Cambridge Structural Database using a shape, complementarity algorithm. The subsequent modification is a non-peptidic, lateral lead, which belongs to a family of compounds with well, characterized pharmacological properties. This thioketal derivative of, haloperidol and a halide counterion are bound within the enzyme active, site in a mode distinct from the observed for peptide-based inhibitors. A, variant of the protease cocrystallized with this inhibitor shows binding, in the manner predicted during the initial computer-based search. The, structures provide the context for subsequent synthetic modifications of, the inhibitor.
+
A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from the observed for peptide-based inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.
==About this Structure==
==About this Structure==
-
2AID is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus Human immunodeficiency virus] with CL and THK as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2AID OCA].
+
2AID is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus Human immunodeficiency virus] with <scene name='pdbligand=CL:'>CL</scene> and <scene name='pdbligand=THK:'>THK</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2AID OCA].
==Reference==
==Reference==
Line 15: Line 14:
[[Category: Human immunodeficiency virus]]
[[Category: Human immunodeficiency virus]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Fauman, E.B.]]
+
[[Category: Fauman, E B.]]
-
[[Category: Keenan, R.J.]]
+
[[Category: Keenan, R J.]]
-
[[Category: Rutenber, E.E.]]
+
[[Category: Rutenber, E E.]]
-
[[Category: Stroud, R.M.]]
+
[[Category: Stroud, R M.]]
[[Category: CL]]
[[Category: CL]]
[[Category: THK]]
[[Category: THK]]
Line 26: Line 25:
[[Category: non-peptide inhibitor]]
[[Category: non-peptide inhibitor]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov 8 14:40:42 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:27:42 2008''

Revision as of 14:27, 21 February 2008


2aid, resolution 1.9Å

Drag the structure with the mouse to rotate

STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN

Overview

A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from the observed for peptide-based inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.

About this Structure

2AID is a Single protein structure of sequence from Human immunodeficiency virus with and as ligands. Active as HIV-1 retropepsin, with EC number 3.4.23.16 Full crystallographic information is available from OCA.

Reference

Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design., Rutenber E, Fauman EB, Keenan RJ, Fong S, Furth PS, Ortiz de Montellano PR, Meng E, Kuntz ID, DeCamp DL, Salto R, et al., J Biol Chem. 1993 Jul 25;268(21):15343-6. PMID:8340363

Page seeded by OCA on Thu Feb 21 16:27:42 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools